Innova Captab

Which are the latest news on Innova Captab?

Why is Innova Captab Ltd falling/rising?

As of 05-Sep, Innova Captab Ltd's stock price is rising to 1,174.45, reflecting a 4.47% increase due to strong financial performance and positive market sentiment. The stock has outperformed the Sensex and its sector, with significant growth in net sales and profit, indicating attractive valuation metrics.

As of 05-Sep, Innova Captab Ltd's stock price is rising, currently at 1,174.45, which reflects an increase of 50.25 (4.47%). This upward movement can be attributed to several positive factors. The stock has shown strong performance over various periods, with a 1-week increase of 11.34% and a 1-month increase of 24.72%, significantly outperforming the Sensex, which has declined by 0.97% and 2.44% respectively during the same time frames. <BR><BR>Today, the stock reached a new 52-week high of Rs 1200, indicating strong market interest. It has been gaining for the last three days, accumulating a total return of 10.88% in this period. Additionally, the stock outperformed its sector by 5.52% today, further highlighting its strength in the market. The trading volume has also seen a rise, with delivery volume increasing by 30.18% compared to the 5-day average, suggesting growing investor participation.<BR><BR>Financially, Innova Captab Ltd demonstrates a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.44 times. The company reported impressive growth in net sales and profit after tax for the nine months ending June 26, with net sales increasing by 39.30% and PAT growing by 31.20%. The stock is trading at a discount compared to its peers, and its return on capital employed (ROCE) stands at 13.9%, indicating attractive valuation metrics.<BR><BR>Overall, the combination of strong financial performance, positive market sentiment, and increasing investor participation contributes to the rising stock price of Innova Captab Ltd.

What does Innova Captab do?

Innova Captab Ltd is a Small Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 471 Cr and a net profit of 44 Cr for June 2026. Key metrics include a P/E ratio of 40.00 and a market cap of INR 6,218 Cr.

Overview:<BR>Innova Captab Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Innova Captab Ltd was incorporated in 2005 under the name 'Harun Health Care Private Limited' and later changed its name in 2010. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 471 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 44 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 6,218 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 40.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.19% <BR>Debt-Equity: 0.27 <BR>Return on Equity: 12.92% <BR>Price to Book: 5.51 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Innova Captab?

Innova Captab's peers include Sanofi India, Senores Pharma, Bliss GVS Pharma, SPARC, Supriya Lifesci, Orchid Pharma, Morepen Labs, IOL Chemicals, FDC, and Guj. Themis Bio, with Bliss GVS Pharma showing the highest 1-year return at 295.64% and Sanofi India the lowest at -39.16%.

Peers: The peers of Innova Captab are Sanofi India, Senores Pharma., Bliss GVS Pharma, SPARC, Supriya Lifesci., Orchid Pharma, Morepen Labs., IOL Chemicals, FDC, and Guj. Themis Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi India and the rest. Average management risk is found at Senores Pharma., Bliss GVS Pharma, SPARC, Orchid Pharma, Morepen Labs., IOL Chemicals, and FDC. Good management risk is noted at Supriya Lifesci. and Guj. Themis Bio. Growth is excellent at Senores Pharma. and SPARC, while below average growth is seen at Sanofi India, Bliss GVS Pharma, Supriya Lifesci., Orchid Pharma, Morepen Labs., IOL Chemicals, FDC, and the rest. Innova Captab shows average growth. Excellent capital structure is present at Sanofi India, Bliss GVS Pharma, Supriya Lifesci., Morepen Labs., IOL Chemicals, and FDC, while good capital structure is found at Senores Pharma. and average capital structure at SPARC and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bliss GVS Pharma at 295.64%, while the lowest is Sanofi India at -39.16%. Innova Captab's 1-year return is 19.67%, which is significantly higher than Sanofi India but lower than Bliss GVS Pharma. Additionally, the peers with negative six-month returns include Sanofi India and FDC.

How big is Innova Captab?

As of 31st August, Innova Captab Ltd has a market capitalization of 6,218.00 Cr, with net sales of 1,749.32 Cr and a net profit of 154.03 Cr reported in the latest four quarters.

As of 31st August, Innova Captab Ltd has a market capitalization of 6,218.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Innova Captab reported net sales of 1,749.32 Cr and a net profit of 154.03 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with shareholder's funds amounting to 1,090.79 Cr and total assets of 1,835.96 Cr.

Should I buy, sell or hold Innova Captab Ltd?

When is the next results date for Innova Captab Ltd?

The next results date for Innova Captab Ltd is 21 August 2026.

The next results date for Innova Captab Ltd is scheduled for 21 August 2026.

Are Innova Captab Ltd latest results good or bad?

Innova Captab Ltd's latest results show strong year-on-year growth in revenue (up 42.28%) and net profit (up 28.78%), but sequential declines in net profit (down 9.66%) and margins raise concerns about profitability challenges. Overall, the results are mixed, indicating both positive growth and emerging issues.

Innova Captab Ltd's latest results present a mixed picture. For the fourth quarter of FY26, the company reported a net profit of ₹38.08 crore, which reflects a decline of 9.66% compared to the previous quarter. However, this figure shows a significant year-on-year increase of 28.78%. <BR><BR>Revenue for the same quarter was ₹447.80 crore, down slightly by 0.55% from the previous quarter but up by an impressive 42.28% year-on-year. Despite this strong revenue growth, the company faced challenges with profitability, as both operating margins and profit after tax (PAT) margins decreased sequentially. The operating margin fell to 14.54%, down from 15.41%, and the PAT margin declined to 8.50% from 9.36%.<BR><BR>Overall, while the year-on-year growth in revenue and profit is encouraging, the sequential declines in both net profit and margins indicate emerging challenges that could raise concerns among investors. The company's ability to manage costs and maintain profitability will be crucial moving forward.

Is Innova Captab technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish due to bearish momentum from the MACD and KST, despite some bullish strength in the RSI, indicating a cautious approach is warranted.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the daily moving averages also reflect a bearish outlook. The weekly RSI shows bullish strength, but this is countered by the bearish signals from the Bollinger Bands. Dow Theory indicates a mildly bullish trend on the weekly chart, but overall, the mixed signals suggest a cautious approach. The stock has underperformed significantly against the Sensex over multiple time frames, further supporting the bearish sentiment.

How has been the historical performance of Innova Captab?

Innova Captab has shown consistent growth over the past three years, with net sales rising from 926.38 Cr in Mar'23 to 1,243.68 Cr in Mar'25, and profit after tax increasing from 67.95 Cr to 128.26 Cr. The company's total assets and liabilities also expanded significantly during this period.

Answer:<BR>The historical performance of Innova Captab shows a consistent growth trajectory in key financial metrics over the past three years.<BR><BR>Breakdown:<BR>Innova Captab's net sales increased from 926.38 Cr in Mar'23 to 1,243.68 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed suit, reaching 1,243.68 Cr in Mar'25, up from 926.38 Cr in Mar'23. The company's total expenditure also rose, from 812.73 Cr in Mar'23 to 1,057.52 Cr in Mar'25, driven by higher raw material costs and employee expenses. Operating profit (PBDIT) improved significantly, climbing from 122.85 Cr in Mar'23 to 198.21 Cr in Mar'25, while profit before tax increased from 91.80 Cr to 171.02 Cr in the same period. Consequently, profit after tax surged from 67.95 Cr in Mar'23 to 128.26 Cr in Mar'25, resulting in an earnings per share (EPS) growth from 14.16 to 22.41. The company's total assets expanded from 704.29 Cr in Mar'23 to 1,568.17 Cr in Mar'25, with total liabilities also increasing from 704.29 Cr to 1,568.17 Cr. Cash flow from operating activities showed variability but ended at 63.00 Cr in Mar'25, while cash flow from financing activities was positive at 91.00 Cr. Overall, Innova Captab has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and liabilities over the past three years.

Is Innova Captab overvalued or undervalued?

As of November 6, 2025, Innova Captab is considered undervalued with an attractive valuation grade, featuring a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, indicating better growth potential compared to peers despite recent underperformance against the Sensex.

As of 6 November 2025, Innova Captab has moved from a fair to attractive valuation grade, indicating a more favorable outlook. The company is currently considered undervalued. Key ratios include a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, which suggests that the stock is priced reasonably relative to its growth potential.<BR><BR>In comparison to its peers, Innova Captab's PE ratio is higher than Sun Pharma's 35.02 but lower than Divi's Lab's significantly high 79.09, indicating a competitive position within the industry. Additionally, while Cipla has a more attractive PE of 22.27, Innova Captab's PEG ratio of 0.99 suggests it offers better growth at its current price. Despite recent underperformance against the Sensex, with a year-to-date return of -26.98% compared to the Sensex's 6.62%, the valuation metrics support a bullish outlook for the stock moving forward.

Who are the top shareholders of the Innova Captab?

The top shareholders of Innova Captab include promoter Manoj Lohariwala with 29.07%, public shareholder Gian Parkash Aggarwal with 21.65%, individual investors with 27.62%, mutual funds holding 10.75%, and foreign institutional investors at 0.34%.

The top shareholders of Innova Captab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Manoj Lohariwala, with a stake of 29.07%. Additionally, Gian Parkash Aggarwal is the highest public shareholder, holding 21.65%. Individual investors collectively own 27.62% of the company. Mutual funds have a presence through 9 schemes, holding 10.75%, while foreign institutional investors (FIIs) hold a smaller portion at 0.34%.

Has Innova Captab declared dividend?

No Dividend History Available